RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Howard Donninger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Louisville, Louisville, Kentucky, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, ral Guanine Nucleotide Exchange Factor, ras Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
RAS oncoproteins are the most frequently activated oncoproteins in cancer. Development of direct RAS inhibitors has proved technically challenging and has had limited success in the clinic. Those RAS inhibitors that have been approved tend to suffer from resistance development. Consequently, many attempts have focused on inhibiting RAS indirectly by targeting its immediate downstream effectors. RAS binds and activates three main effector classes to drive transformation: RAF kinases, phosphoinositide 3 (PI-3) kinase and Ras-like (RAL) small GTPases (RALGEF) exchange factors. Multiple FDA-approved inhibitors for RAF and PI-3 kinase exist. So far, they have proved to be of limited effectiveness in patients. However, no inhibitors of the RALGEF effectors with demonstrated antitumor activity have been reported. This is despite the considerable body of evidence supporting a critical role for the RALGEF/RAL pathway in facilitating the in vivo transforming effects of activated RAS. Here, we describe the first small molecule pan-RALGEF inhibitor. We show the inhibitor specifically suppresses RAS/RAL signaling and exhibits antitumor effects in xenograft experiments, including a patient-derived xenograft (pdx) model. This first-in-class compound may lead to the development of more effective therapies for a broad range of RAS-driven tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA.
- University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA. Electronic address: gjclar01@louisville.edu.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Donninger, H., Ferrill, R., von Baby, B., Hobbing, K. R., Dean, W. L., Miriyala, N., Jigo, R., Burlison, J., Trent, J. O., Monsen, R., & Clark, G. J. (2025). RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110809
Vancouver
Donninger H, Ferrill R, von Baby B, Hobbing KR, Dean WL, Miriyala N, et al. RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110809
BibTeX
@article{Donninger2025,
author = {Donninger, Howard and Ferrill, Rachel and von Baby, Becca and Hobbing, Katie R and Dean, William L and Miriyala, Nagaraju and Jigo, Raphael and Burlison, Joseph and Trent, John O and Monsen, Robert and Clark, Geoffrey J},
title = {RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110809}
}
EUVIMED